Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities ...

Liver cancer can arise spontaneously from healthy liver tissue. Recently, however, researchers have discovered an increasing ...

The following is a summary of "Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC," published in the April 2025 issue of BMC Cancer by ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at ...

Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

LIVER cancer is the fourth most common cancer in Malaysia and also the fourth leading cause of cancer-related deaths.

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...